5Sakaeda T, Kadoyama K, Okuno Y. Statin associated muscu- lar and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011,6(12) :e28124.
6Takarabe M, Kotera M, Nishimura Y, et al. Drug target pre diction using adverse event report systems: a pharmacogenom- ic approach. Bioinformatics, 2012,28(18) : i611-i618.
7HoffmanKB, KrausC, DimbilM,etal. A surveyoftheFDA 's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One, 2012, 7 (8): e42866.
8Harpazl R, Du Mouchel W, Shah NH,et al. Novel data-min ing methodologies for adverse drug event discovery and analy sis[J]. Clin Pharmaeol Ther, 21112, 91 (6) : 1010-1021.
